Cavanal Hill Funds has filed its latest NPORT-P report, indicating total assets of approximately $108.7 million as of August 31, 2026. This filing is significant as it provides insight into the fund's financial health and investment strategy, which could influence investor confidence in the firm.
The company, incorporated in Ohio, operates in the investment management sector. It has undergone name changes in the past, previously known as American Performance Funds and American Plus Funds. The recent filing, dated October 29, 2026, is part of a series of NPORT-P filings made on the same day, reflecting ongoing compliance with regulatory requirements.
According to the filing, Cavanal Hill Funds reported total liabilities of approximately $486,058. This results in net assets of around $108.2 million. The fund's portfolio includes a variety of securities, with notable holdings in corporate debt and asset-backed securities.
Key highlights from the filing include:
Total Assets: $108,692,974.63
Total Liabilities: $486,058.11
Net Assets: $108,206,916.52
The filing also details the fund's investment strategy, showcasing a diversified portfolio that includes securities from various sectors. This diversification may help mitigate risks associated with market fluctuations.
Investors and analysts will be particularly interested in the fund's performance metrics, which indicate fluctuations in monthly total returns across different classes of shares. For instance, the Bond Fund class reported a monthly return of 0.44% in the first month, followed by a decline of 1.55% in the second month.
As the investment management sector continues to evolve, Cavanal Hill Funds' latest filing may serve as a benchmark for other firms in the industry. Competitors will likely analyze these results to gauge market trends and investor sentiment.
What's next for Cavanal Hill Funds remains unclear, as the filing does not specify any upcoming actions or changes. However, continued monitoring of their filings will provide further insights into their operational strategies and market positioning.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






